Health Care & Life Sciences » Biotechnology | Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,908.60
4,594.10
17,893.90
13,110.00
13,429.00
10,594
Depreciation, Depletion & Amortization
9.10
6.60
6.00
3.00
1.00
3
Other Funds
-
181.00
43.10
-
-
3,915
Funds from Operations
4,592.20
3,138.10
2,008.40
3,916.00
6,979.00
6,676
Changes in Working Capital
2,123.50
2,377.30
1,744.50
586.00
773.00
1,125
Net Operating Cash Flow
6,715.70
5,515.50
3,752.80
4,502.00
6,206.00
7,801
Capital Expenditures
6.50
3.50
-
2.00
-
Net Investing Cash Flow
6.50
3.50
-
2.00
-
Issuance/Reduction of Debt, Net
-
944.30
-
-
-
Net Financing Cash Flow
5,987.60
5,855.80
3,495.00
6,147.00
5,039.00
Net Change in Cash
734.60
336.70
257.80
1,643.00
1,167.00
Free Cash Flow
6,722.20
5,519.00
3,752.80
4,504.00
6,206.00
Deferred Taxes & Investment Tax Credit
-
52.00
-
-
-
-
Change in Capital Stock
5,987.60
5,092.50
3,538.10
6,147.00
5,039.00

About Nymox Pharmaceutical

View Profile
Address
Bay & Deveaux Streets
Nassau NW
Bahamas
Employees -
Website http://www.nymox.com
Updated 07/08/2019
Nymox Pharmaceutical Corp.operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.